| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2017PLoSO..1270874O |
| P356 | DOI | 10.1371/JOURNAL.PONE.0170874 |
| P932 | PMC publication ID | 5266335 |
| P698 | PubMed publication ID | 28122064 |
| P50 | author | Ji Yong Jung | Q59546716 |
| P2093 | author name string | Wookyung Chung | |
| Yun Jung Oh | |||
| Sun Moon Kim | |||
| Jae Hyun Chang | |||
| Han Ro | |||
| Hyun Hee Lee | |||
| Byung Chul Shin | |||
| Hyun Lee Kim | |||
| Jong Hoon Chung | |||
| Ae Jin Kim | |||
| Chungsik Lee | |||
| P2860 | cites work | Aldosterone antagonists for preventing the progression of chronic kidney disease | Q24194979 |
| Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency | Q80313261 | ||
| Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotens | Q80796915 | ||
| Does evidence support renin-angiotensin system blockade for slowing nephropathy progression in elderly persons? | Q83854659 | ||
| The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease | Q84699464 | ||
| Comments on 'KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease' | Q87330015 | ||
| Losartan and diabetic nephropathy: commentaries on the RENAAL study | Q24796010 | ||
| Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients | Q27023161 | ||
| Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes | Q28188162 | ||
| Use of a marginal structural model to determine the effect of aspirin on cardiovascular mortality in the Physicians' Health Study | Q28193086 | ||
| Cardiorenal end points in a trial of aliskiren for type 2 diabetes | Q28278569 | ||
| Prevalence of chronic kidney disease in the United States | Q29614191 | ||
| Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy | Q29615215 | ||
| 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8) | Q29617334 | ||
| Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) | Q29618529 | ||
| Marginal structural models and causal inference in epidemiology | Q29619287 | ||
| Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. | Q31383623 | ||
| Evaluating health management programmes over time: application of propensity score-based weighting to longitudinal data | Q33549560 | ||
| Efficacy and safety of benazepril for advanced chronic renal insufficiency | Q33992851 | ||
| Impact of age and overt proteinuria on outcomes of stage 3 to 5 chronic kidney disease in a referred cohort | Q34281450 | ||
| Diabetic nephropathy: diagnosis, prevention, and treatment | Q34379284 | ||
| Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis | Q34412986 | ||
| Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria | Q34504490 | ||
| Epidemiology of anemia associated with chronic renal insufficiency | Q34617890 | ||
| Time to re-evaluate effects of renin-angiotensin system inhibitors on renal and cardiovascular outcomes in diabetic nephropathy | Q35050798 | ||
| Outcome beyond blood pressure control? | Q35087930 | ||
| Dialysis registries in the world: Korean Dialysis Registry | Q35682126 | ||
| Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis | Q36336393 | ||
| Brief Report: Renal replacement therapy in Korea, 2010 | Q36468614 | ||
| Acute renal failure in the elderly: particular characteristics. | Q36679512 | ||
| Progression of renal disease: renoprotective specificity of renin-angiotensin system blockade | Q36910471 | ||
| Late onset azotemia from RAAS blockade in CKD patients with normal renal arteries and no precipitating risk factors | Q37057985 | ||
| Reno-prevention vs. reno-protection: a critical re-appraisal of the evidence-base from the large RAAS blockade trials after ONTARGET--a call for more circumspection | Q37355390 | ||
| Interaction of aging and chronic kidney disease | Q37408956 | ||
| National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification | Q39513412 | ||
| The incidence of end-stage renal disease is increasing faster than the prevalence of chronic renal insufficiency | Q40495060 | ||
| Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Patients Without Heart Failure? Insights From 254,301 Patients From Randomized Trials | Q40979692 | ||
| ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy | Q43812834 | ||
| Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy. | Q43829718 | ||
| Estimating the causal effect of zidovudine on CD4 count with a marginal structural model for repeated measures | Q45306426 | ||
| The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension | Q46169157 | ||
| Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. | Q46426098 | ||
| Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLH | Q46455413 | ||
| Aliskiren combined with losartan in type 2 diabetes and nephropathy | Q46558669 | ||
| Late-onset renal failure from angiotensin blockade (LORFFAB) in 100 CKD patients | Q46807546 | ||
| Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia | Q48385727 | ||
| US Renal Data System 2015 Annual Data Report: Epidemiology of Kidney Disease in the United States. | Q51302097 | ||
| Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease. | Q51915845 | ||
| 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). | Q55057254 | ||
| ACE-inhibitor use and the long-term risk of renal failure in diabetes | Q57446641 | ||
| Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy | Q57704237 | ||
| Prevalence of Anemia and Its Impact on Mortality and Hospitalization Rate in Predialysis Patients | Q59361716 | ||
| Angiotensin-converting enzyme inhibition and renovascular disease | Q68643439 | ||
| The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group | Q70513402 | ||
| Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group | Q70989850 | ||
| Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) | Q73499190 | ||
| Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group | Q73632528 | ||
| Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994) | Q74331944 | ||
| Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group | Q77223580 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | renal dialysis | Q202301 |
| P304 | page(s) | e0170874 | |
| P577 | publication date | 2017-01-25 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | The Impact of Renin-Angiotensin System Blockade on Renal Outcomes and Mortality in Pre-Dialysis Patients with Advanced Chronic Kidney Disease | |
| P478 | volume | 12 |
Search more.